Limits...
Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.


Related in: MedlinePlus

Li’s vaccine consisting of the glycopeptide antigen and the T-cell epitope [20].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f001: Li’s vaccine consisting of the glycopeptide antigen and the T-cell epitope [20].

Mentions: Carrier proteins are widely used in commercially available combined vaccines. Carrier proteins, which have lots of antigens, are highly immunogenic. Therefore, the conjugation of antigens with carrier proteins, such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), could improve immune response against the desired antigens. Kunz and co-workers conjugated TF-modified or STn-modified MUC1 glycopeptide to TT and found that these conjugates elicited a high-level immune response [17,18]. The IgG antibody elicited by these vaccines recognized not only tumor cells, but also tumor tissues from patients [19]. Li and co-workers conjugated a series of MUC1 glycopeptides to BSA as vaccine candidates and found that glycosylation at the Thr residue in the PDTRP domain played important roles in eliciting the immune response (Figure 1) [20]. However, carrier proteins often elicit a high-level of immune response against themselves, which is probably not useful for immunotherapy against the desired antigens.


Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Li’s vaccine consisting of the glycopeptide antigen and the T-cell epitope [20].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f001: Li’s vaccine consisting of the glycopeptide antigen and the T-cell epitope [20].
Mentions: Carrier proteins are widely used in commercially available combined vaccines. Carrier proteins, which have lots of antigens, are highly immunogenic. Therefore, the conjugation of antigens with carrier proteins, such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), could improve immune response against the desired antigens. Kunz and co-workers conjugated TF-modified or STn-modified MUC1 glycopeptide to TT and found that these conjugates elicited a high-level immune response [17,18]. The IgG antibody elicited by these vaccines recognized not only tumor cells, but also tumor tissues from patients [19]. Li and co-workers conjugated a series of MUC1 glycopeptides to BSA as vaccine candidates and found that glycosylation at the Thr residue in the PDTRP domain played important roles in eliciting the immune response (Figure 1) [20]. However, carrier proteins often elicit a high-level of immune response against themselves, which is probably not useful for immunotherapy against the desired antigens.

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.


Related in: MedlinePlus